These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 29982565)

  • 1. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
    Sader HS; Mendes RE; Pfaller MA; Flamm RK
    J Antimicrob Chemother; 2019 May; 74(5):1306-1310. PubMed ID: 30753485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
    Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.
    Jones RN; Farrell DJ; Flamm RK; Sader HS; Dunne MW; Mendes RE
    Diagn Microbiol Infect Dis; 2015 May; 82(1):73-7. PubMed ID: 25724854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
    Jones RN; Sader HS; Flamm RK
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci.
    Neudorfer K; Schmidt-Malan SM; Patel R
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):58-63. PubMed ID: 29195766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection].
    Yang QW; Wang H; Sun HL; Xu YC; Xie XL; Chen MJ
    Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):220-4. PubMed ID: 19576091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
    Aktaş G; Bozdoğan B; Derbentli S
    Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
    Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
    Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020).
    Sader HS; Castanheira M; Huband MD; Shortridge D; Carvalhaes CG; Mendes RM
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):867-873. PubMed ID: 35355158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.